Thrivent Financial for Lutherans Acquires 65,050 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Thrivent Financial for Lutherans increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 150.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 108,258 shares of the company’s stock after purchasing an additional 65,050 shares during the quarter. Thrivent Financial for Lutherans owned 0.13% of IDEXX Laboratories worth $54,693,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Chicago Partners Investment Group LLC increased its stake in IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after purchasing an additional 96 shares in the last quarter. Manning & Napier Advisors LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $20,418,000. Oppenheimer Asset Management Inc. grew its stake in shares of IDEXX Laboratories by 13.8% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock worth $5,825,000 after acquiring an additional 1,453 shares in the last quarter. National Pension Service grew its stake in shares of IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company’s stock worth $93,957,000 after acquiring an additional 12,647 shares in the last quarter. Finally, EFG Asset Management Americas Corp. grew its stake in shares of IDEXX Laboratories by 45.3% during the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company’s stock worth $6,201,000 after acquiring an additional 3,966 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. JPMorgan Chase & Co. decreased their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. BTIG Research initiated coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price for the company. Finally, Barclays decreased their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $552.38.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $419.83 on Tuesday. IDEXX Laboratories, Inc. has a 12-month low of $404.74 and a 12-month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The business’s 50-day moving average price is $467.11 and its two-hundred day moving average price is $482.44. The stock has a market cap of $34.38 billion, a PE ratio of 40.49, a P/E/G ratio of 3.67 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter in the previous year, the business posted $2.53 earnings per share. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. As a group, analysts expect that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.